Reports Q3 revenue $701.3M, consensus $643.24M. “Fortrea (FTRE) delivered a solid performance that met expectations in the Q3 by partnering with our clients and advancing the development of potentially life-changing treatments for patients,” said Anshul Thakral, CEO of Fortrea. “I’m pleased with how our strong team moved quickly through our leadership transition without missing a beat. I have spent my first few months connecting with clients and meeting with colleagues across the globe to build a holistic view of Fortrea today. I am confident that we have the global footprint, differentiated capabilities, therapeutic expertise, technology and innovation needed to deliver on our goals. We are committed to executing our plans with operational, commercial and financial excellence.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FTRE:
- Fortrea and GE Healthcare’s New Diagnostic Study: A Potential Game-Changer in Cancer Detection
- Fortrea’s Phase 1 Study on D3S-001: Evaluating Food’s Impact on Drug Absorption
- Fortrea’s Phase 3 Study on AP301: A Potential Game-Changer for Hyperphosphatemia Treatment
- Fortrea’s Givinostat Study: A New Hope for Young DMD Patients
- Fortrea’s Phase 1 PET Study: A Potential Game-Changer in Diagnostic Imaging